Related Experiment Videos
Circulating immune complexes in patients with lymphomas and leukemias
Neoplasma
|January 1, 1984
Summary
Immune complexes (IC) are more prevalent in non-Hodgkin's lymphoma (NHL) and leukemia patients than healthy individuals. Elevated IC levels correlate with unfavorable prognoses and disease relapse, aiding in patient monitoring.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Immune complexes (IC) play a role in various immune responses.
- Their presence and levels can be indicative of disease states, particularly in hematological malignancies.
Purpose of the Study:
- To investigate the prevalence of immune complexes in patients with non-Hodgkin's lymphoma (NHL) and leukemia.
- To assess the correlation between IC levels and patient prognosis and disease status.
Main Methods:
- Sera from 100 NHL patients, 80 leukemia patients, and 55 healthy controls were analyzed for IC using the EA-rosette forming cell inhibition assay.
- A 9% rosette inhibition threshold was used as a baseline for positive IC detection.
Main Results:
- IC were detected in 66% of NHL patients, 43.7% of leukemia patients, and 18% of controls (p < 0.001).
- NHL patients with unfavorable prognoses showed significantly higher IC prevalence (80%) compared to those with favorable prognoses (45%).
- Leukemic patients exhibited higher IC levels during blastic stages and relapse compared to remission.
Conclusions:
- Immune complex detection is a valuable biomarker in NHL and leukemia.
- Monitoring IC levels can aid in accurately determining patient prognosis and guiding follow-up strategies.